Endothelial Perfusion Biomarkers for Early Shock Recognition

Abstract

Early recognition of shock is pivotal for optimizing outcomes in critically ill patients, as delayed intervention is associated with increased morbidity and mortality. Endothelial dysfunction is a hallmark of shock syndromes, and recent research has identified several endothelial perfusion biomarkers that may serve as reliable early indicators. This review synthesizes current evidence on the utility of endothelial biomarkers for early shock detection, focusing on their pathophysiological basis, clinical relevance, and practical integration in critical care settings. By examining both established and emerging biomarkers, this article aims to inform clinicians about the evolving landscape of shock diagnosis and guide evidence-based practice.

Introduction

Shock, defined as a state of circulatory failure leading to inadequate tissue perfusion and cellular oxygenation, encompasses a spectrum of etiologies including septic, cardiogenic, hypovolemic, and distributive forms. Rapid recognition and intervention are crucial to reverse hemodynamic compromise and prevent irreversible organ dysfunction. Traditional markers such as blood pressure and lactate are often late indicators, prompting the search for sensitive and specific biomarkers that reflect early endothelial perturbation. Endothelial perfusion biomarkers, by signaling microvascular dysfunction and subclinical hypoperfusion, offer a promising approach to timely shock recognition and intervention in both emergency and intensive care settings.

Epidemiology / Disease Burden

Shock remains a significant global health concern, contributing to substantial morbidity, mortality, and healthcare resource utilization. Sepsis-induced shock alone accounts for millions of deaths annually worldwide, with hospital mortality rates ranging from 20% to over 50% depending on severity and comorbidities. Non-septic forms of shock, including hemorrhagic and cardiogenic etiologies, also carry high risk for adverse outcomes. The burden is amplified by the challenge of early diagnosis, as classical signs may be absent or masked in initial stages. The identification and validation of endothelial perfusion biomarkers therefore have profound implications for improving early detection, guiding therapeutic interventions, and reducing the global burden of shock-related deaths.

Pathophysiology

Endothelial cells form the inner lining of blood vessels and regulate vascular tone, permeability, coagulation, and leukocyte trafficking. In shock states, a cascade of inflammatory mediators, pathogen-associated molecular patterns, and hypoxic insults disrupt endothelial integrity, resulting in increased vascular permeability, microthrombi formation, and impaired tissue oxygen delivery. Key molecular events include activation of the glycocalyx, release of adhesion molecules (e.g., ICAM-1, VCAM-1), and shedding of syndecan-1. The resultant microcirculatory dysfunction precedes overt hemodynamic collapse, making endothelial biomarkers attractive candidates for early shock detection.

Risk Factors

Risk factors for developing shock and associated endothelial dysfunction include advanced age, pre-existing cardiovascular or metabolic disease, immune compromise, and chronic inflammatory states. Specific risk stratification tools have incorporated comorbidities, laboratory parameters, and clinical scores, but often lack sensitivity for early microvascular alterations. Conditions such as diabetes mellitus, chronic hypertension, and previous vascular injury may prime the endothelium for exaggerated responses to stress, increasing susceptibility to shock and its complications.

Clinical Features

Early clinical signs of shock are often subtle, including mild tachycardia, altered mental status, and cool extremities. As shock progresses, hypotension, oliguria, lactic acidosis, and organ dysfunction become evident. However, these features may lag behind microcirculatory changes. Biomarkers reflective of endothelial injury—such as elevated syndecan-1, angiopoietin-2, and soluble thrombomodulin—correlate with subclinical perfusion deficits and may precede traditional indicators, offering clinicians an opportunity for preemptive intervention.

Diagnosis

Diagnosis of shock traditionally relies on clinical assessment, vital sign monitoring, and laboratory parameters such as serum lactate and base deficit. Endothelial perfusion biomarkers provide an adjunctive diagnostic approach, enabling detection of microvascular dysfunction before overt hemodynamic collapse. Syndecan-1, a marker of glycocalyx degradation, and angiopoietin-2, an endothelial destabilizer, have demonstrated prognostic value in sepsis and trauma. Soluble thrombomodulin and ICAM-1 also reflect endothelial activation and injury, correlating with disease severity and outcomes. Integration of these biomarkers into diagnostic algorithms may enhance risk stratification and guide early resuscitative efforts.

Treatment & Management

The cornerstone of shock management is early identification, prompt resuscitation, and targeted therapy based on etiology. Endothelial biomarkers can inform treatment decisions by identifying patients at risk for rapid deterioration, guiding fluid resuscitation, and monitoring response to therapy. For example, persistent elevation of syndecan-1 or angiopoietin-2 may indicate ongoing endothelial injury, prompting reassessment of resuscitation strategies or escalation to advanced hemodynamic support. Additionally, therapies targeting endothelial stabilization, such as hydrocortisone or vitamin C in septic shock, are under investigation and may be tailored based on biomarker profiles.

Recent Advances / Emerging Therapies

Recent research has expanded the repertoire of endothelial biomarkers and explored their integration with advanced monitoring modalities. Novel assays for real-time measurement of syndecan-1, angiopoietin-2, and microvesicles are being developed, enabling point-of-care assessment. Multi-biomarker panels and machine learning-based predictive models are also under investigation to improve diagnostic accuracy and prognostication. Emerging therapies aimed at preserving the endothelial glycocalyx, modulating inflammatory responses, and restoring microvascular perfusion hold promise for improving outcomes in shock syndromes. Early-phase trials evaluating the efficacy of adjunctive therapies guided by endothelial biomarkers are ongoing, with initial results suggesting potential benefit in select patient populations.

Guideline Recommendations

International guidelines, such as those from the Surviving Sepsis Campaign and the European Society of Intensive Care Medicine, recognize the critical role of early shock recognition and endorse the use of biomarkers for risk stratification. While lactate remains the primary biochemical marker recommended for clinical use, there is growing interest and cautious endorsement of endothelial biomarkers as adjuncts for early diagnosis and monitoring. Ongoing research and validation studies are required before widespread adoption, but current guidelines encourage participation in clinical trials and integration of emerging evidence into practice where feasible.

Conclusion

Endothelial perfusion biomarkers represent a promising frontier in the early recognition and management of shock. By providing sensitive indicators of microvascular dysfunction, these biomarkers offer clinicians a valuable tool for timely diagnosis, risk stratification, and personalized therapy. While challenges remain in standardization and validation, ongoing research continues to refine their clinical utility. Integration of endothelial biomarkers into routine practice has the potential to improve patient outcomes, reduce morbidity and mortality, and transform the landscape of shock management in critical care.